Quantitative analysis for Cue Biopharma, Inc. (CUE) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (70.0) (grade B). 25 signals analyzed (21 differentiated alt-data).
CUE stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $17.20 | $10.76 | $12.45 |
| 2026-05-08 | $36.98 | $34.01 | $35.00 |
| 2026-05-20 | $21.34 | $19.89 | $20.43 |
| 2026-06-02 | $29.04 | $24.80 | $28.62 |
| 2026-06-12 | $28.94 | $23.20 | $24.53 |
| 2026-06-25 | $26.88 | $24.65 | $25.54 |
| 2026-07-08 | $36.99 | $30.92 | $35.35 |
| 2026-07-20 | $32.50 | $29.45 | $30.95 |
| 2026-07-30 | $31.84 | $27.15 | $30.40 |
| 2026-08-12 | $31.00 | $26.59 | $30.42 |
| 2026-08-24 | $24.19 | $22.56 | $23.18 |
| 2026-09-03 | $28.09 | $26.60 | $27.67 |
How Cue Biopharma, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. Common Stock | $53M | — |
| ELUT | Elutia Inc. | $52M | — |
| ACRV | Acrivon Therapeutics, Inc. Common Stock | $56M | — |
| NRXP | NRx Pharmaceuticals, Inc. | $51M | — |
View all Health Care stocks by valuation and signals →
Cue Biopharma, Inc. (CUE) scores Buy (70.0), and the composite conceals a 93-point disagreement between its dimensions. It is strongest on analyst consensus at 94 and technicals at 77, and weakest on competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 94 |
| technicals | 77 |
| competitive moat | 1 |
StoQuant analyzes 25 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Cue Biopharma, Inc. (CUE): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CUE"><img src="https://stoquant.com/badge/CUE.svg" alt="Cue Biopharma, Inc. (CUE) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.